Clinical Trial Update: Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 trial assessing whether rifampin alters the pharmacokinetics of dapagliflozin in healthy subjects; the study status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus | Phase 1 | Status: TERMINATED